DARE NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Dare Bioscience Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 1.22 USD
-4.7% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -36.4% below the Trend Line and sits at 3.4% of its 52-week range. The latest completed week returned -4.7%, after a -41.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 49/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 15 out of 100
Latest Close 1.22 USD 31 Jul 2026
1W Return -4.7% latest completed week
4W Return -41.6% short-term follow-through
12W Return -55.6% quarterly tape
Trend Breadth 21.2% 11 of 52 weeks active
Volume Ratio 0.3x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -4.7% Latest completed week; four-week move -41.6%. Indicator stack 12/0 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 49/100 41 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -36.4% below the Trend Line and sits at 3.4% of its 52-week range. The latest completed week returned -4.7%, after a -41.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2812-week average 0.37

12-week confirmation

Trend active10/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.28Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -41.6% over four weeks, -55.6% over 12 weeks, and -49.6% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-4.7%
4W-41.6%
12W-55.6%
26W-32.6%
52W-49.6%
Active trend streak0 weeks
Active weeks in one year11
Trend breadth21.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.84Latest activity-pressure read.
Pressure change-854.4%Four-week change in activity pressure.
Leadership-43.20Latest relative-leadership reading.
RS change-297.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 73% Model confidence 70%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength65/100Blend of value, momentum, and quality. Underlying universe rank 36; rank 1 is best.
Value57/100Relative valuation strength. Underlying universe rank 44; rank 1 is best.
Quality55/100Profitability and accounting quality. Underlying universe rank 46; rank 1 is best.
Momentum57/100Medium-term price momentum. Underlying universe rank 44; rank 1 is best.
Growth57/100Revenue and earnings growth. Underlying universe rank 44; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
16.6x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-414.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-96.0%
Gross profit retained from each unit of revenue.
Operating margin
-998.3%
Operating profit retained from revenue.
Free-cash-flow margin
-812.4%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-217.2%
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.8x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity10 / 0

10 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment49/100

Weighted news tone is neutral across 41 relevant articles.

4 positive · 34 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-67.7%Distance below the 52-week high.
13-week volatility13.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2614 weeks finished lower.
Best week+61.2%Week of 17 Apr.
Worst week-34.7%Week of 24 Jul.
Latest week-4.7%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains2
Flat weeks1
Modest losses4
Sharp losses10
Recent vol13.3%13-week weekly-return volatility.
Base vol14.4%52-week weekly-return volatility.
Up/down split22/29Count of positive and negative weeks in the 52-week window.
Average skew10.6% / -8.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape17/100

Trend, activity pressure, participation, and risk combine to a 17/100 tape read.

 Indicator analysis48/100

Latest 12-week confirmation: trend 10/12, activity pressure 8/12, relative leadership 0/12.

Activity pressure 0.28; No reversal markers Factors58/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment49/100

Weighted news tone is neutral across 41 relevant articles.

DARE|Dare Bioscience Inc|Price:1.230|Chg%:-0.010 Insiders10 / 0

10 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20261.22 USD-4.7%1.92 USD3.38 USD-0.84-43.20639.3KOff
24 Jul 20261.28 USD-34.7%1.94 USD3.42 USD-0.55-41.032.2MOff
17 Jul 20261.96 USD-3.0%1.97 USD3.47 USD-0.23-12.57611.5KOn
10 Jul 20262.02 USD-3.3%1.97 USD3.52 USD-0.03-14.50462.2KOn
3 Jul 20262.09 USD0.0%1.99 USD3.57 USD0.11-10.87506.4KOn
26 Jun 20262.09 USD-3.7%1.98 USD3.63 USD0.18-10.83794.1KOn
19 Jun 20262.17 USD7.4%1.97 USD3.68 USD0.30-12.28900.1KOn
12 Jun 20262.02 USD7.4%1.95 USD3.74 USD0.44-17.32675.6KOn
5 Jun 20261.88 USD-15.7%1.95 USD3.80 USD0.63-22.581.1MOn
29 May 20262.23 USD-5.9%1.95 USD3.87 USD0.92-13.94953.1KOn
22 May 20262.37 USD9.2%1.94 USD3.93 USD1.05-7.272.0MOn
15 May 20262.17 USD-21.1%1.93 USD3.99 USD1.13-15.174.6MOn
8 May 20262.75 USD17.5%1.93 USD4.06 USD1.255.759.2MOn
1 May 20262.34 USD10.9%1.90 USD4.11 USD0.98-6.111.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.